BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vemurafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vemurafenib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06440850-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT06440850)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Vemurafenib and Cobimetinib for 
 the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma 
 With BRAFV600E Mutation\nEstimated primary completion: 22 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06440850
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: A Study of Multiple Therapies in
  Biomarker-selected Participants With Resectable Stages IB-III Non-small C
 ell Lung Cancer (NSCLC)\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008119-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Vemurafenib: Phase 3 readout est. (NCT06008119)
DESCRIPTION:Vemurafenib\, phase 3.\nStudy: Efficacy and Safety of Tunlameti
 nib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorec
 tal Cancer\nEstimated primary completion: 24 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06008119
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Canadian Profiling and Targeted 
 Agent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297
 606
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03410875-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT03410875)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: A Phase II Study of the BRAF Inh
 ibitor\, Vemurafenib\, Plus Obinutuzumab in Patients With Previously Untre
 ated Classical Hairy Cell Leukemia\nEstimated primary completion: January 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0341087
 5
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04943198-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT04943198)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Optimization of the Time and Dos
 age of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Hist
 iocytosis\nEstimated primary completion: 30 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04943198
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vemurafenib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Vemurafenib\, phase 2/3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Multiple Targeted Therapies as Treatments for Participant
 s With Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafe
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03178552
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03181100-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT03181100)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Atezolizumab With Chemotherapy i
 n Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cance
 r\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03181100
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561360-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT06561360)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: A Study of Vemurafenib and Obinu
 tuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leu
 kemia (HCL)\nEstimated primary completion: 9 September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06561360
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 emurafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: TAPUR: Testing the Use of Food a
 nd Drug Administration (FDA) Approved Drugs That Target a Specific Abnorma
 lity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/vemurafenib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Vemurafenib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Vemurafenib\, phase 3.\nStudy: A Study in Patients Previously E
 nrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizu
 mab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01709292-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT01709292)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: Vemurafenib Neoadjuvant Trial in
  Locally Advanced Thyroid Cancer\nEstimated primary completion: 30 Septemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0170
 9292
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: ProTarget - A Danish Nationwide 
 Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEs
 timated primary completion: 30 April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vemurafenib: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Vemurafenib\, phase 4.\nStudy: The FLOTILLA Study: Providing Co
 ntinued Access to The Study Medicines Encorafenib and Binimetinib for Part
 icipants in Prior Clinical Trials\nEstimated primary completion: 31 July 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768178-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Vemurafenib: Phase 2/3 readout est. (NCT05768178)
DESCRIPTION:Vemurafenib\, phase 2/3\, Melanoma.\nStudy: DETERMINE Trial Tre
 atment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patien
 ts With BRAF Positive Cancers.\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/vemurafenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05768178
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Vemurafenib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Vemurafenib\, phase 2/3.\nStudy: DETERMINE (Determining Extende
 d Therapeutic Indications for Existing Drugs in Rare Molecularly Defined I
 ndications Using a National Evaluation Platform Trial) - Master Screening 
 Protocol\nEstimated primary completion: October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2273@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Vemurafenib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Vemurafenib\, phase 2.\nStudy: The Finnish National Study to Fa
 cilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary c
 ompletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/vemurafenib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
